A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

This is a post-approval monitoring study in South Korea tracking how well capmatinib (brand name Tabrecta) works in real-world clinical settings. Capmatinib is a targeted therapy approved for a specific type of lung cancer with a mutation called MET exon 14 skipping. **You may be eligible if...** - You have been diagnosed with non-small cell lung cancer (NSCLC) with a MET exon 14 skipping mutation (confirmed by tumor tissue or blood test) - Your doctor has prescribed capmatinib (Tabrecta) as part of your standard treatment - You have signed informed consent **You may NOT be eligible if...** - You have a medical reason why capmatinib is contraindicated for you - Your medical records cannot be accessed for the study - You are unwilling to provide informed consent Talk to your doctor to see if this trial is right for you.